Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITD
Target Price
The average target price of BIOA-B.ST is 307 and suggests 4% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell